Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Top Research Reports For Boeing, GM, UnitedHeal

Published 10/27/2016, 11:17 PM
Updated 07/09/2023, 06:31 AM
BA
-
GM
-
BARC
-
FI
-
GD
-
BSX
-
TXN
-

Friday, October 28, 2016

Today's Research Daily features new research reports on 16 major stocks, including Boeing (NYSE:BA), General Motors (NYSE:GM), UnitedHealth (UNH) and Honeywell (HON).

Boeing shares lagged the broader market and the peer aerospace group for much of this year, but they have outperformed both over the past month. The company's better than expected September quarter results and positivie guidance should help sustain this momentum. In the updated research report issued today, the Zacks analyst discusses the pros & cons of investing in Boeing shares. The analyst likes the company’s expansion on the international front, as well as its strong presence in the domestic aviation market. However, Boeing continues to face challenges such as declining backlog, uncertainty surrounding high-cost programs, lower delivery numbers and stiff competition. (You can read the full research report on Boeing here>>)

General Motors shares continue to struggle (the stock is down roughly 8% year to date), with market sentiment refusing to budge despite the record third-quarter results and positive guidance. Market participants appear to be concerned about where we go from the current robust environment, with the outlook for pricing and Europe, particularly post-Brexit, as key issues. These macro worries notwithstanding, the automaker's earnings and cash flow outlook remains very favorable, with analysts steadily raising their estimates. (You can read the full research report on General Motors here>>)

Buy rated UnitedHealth shares have gained more than 20% year-to-date. UnitedHealth Group’s earnings beat expectations, led by strong results from the health services business, Optum, and membership growth. The company also raised its outlook for 2016 adjusted earnings to approximately $8 per share. The analyst stresses that UnitedHealth is consistently gaining from the Medicaid and Medicare businesses. Continued growth at Optum is also leading to a diversified revenue source. Also, UnitedHealth should benefit from its capital strength and niche market position. (You can read the full research report on UnitedHealth here>>)

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Shares of Honeywell have moved lower in recent months. Honeywell reported strong third-quarter 2016 earnings, and has also completed key divestitures. The analyst likes the fact that Honeywell remains focused on increasing its presence in high-growth regions. Additionally the company is building a robust pipeline of new products. However, adverse foreign currency translations and volatility in commodity prices related to Brexit are likely to peg back its growth momentum slightly. (You can read the full research report on Honeywell here>>)

Other noteworthy reports we are featuring today include 3M (MMM), Barclays (LON:BARC) (BCS) and Colgate Palmolive (CL).

Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. Today Steve is also opening up Zacks' 7 Best Stocks for October, 2016 free of charge. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout. Click to access these private picks>>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Featured Reports

Colgate (CL) Posts Q3 In-Line Earnings, Sales Miss Estimates

The Zacks analyst think Colgate's third quarter results were impacted by currency woes and tough macro conditions. While these hurdles are expected to linger in 2016, Colgate retained its outlook.

Northrop (NOC) Tops Q3 Earnings, Sales; Hikes EPS View

The covering analyst believes Northrop's better-than-expected Q3 results and its strong fundamentals encouraged management to raise FY16 View. Earnings also rose from the year ago quarter.

American Tower's (AMT) Overseas Operations to Drive Growth

The Zacks analyst believes that American Tower's international operations will be the major driver for revenue growth going forward.

Schwab (SCHW) Q3 Results Show Persistent Fall in Fee Waivers

The covering analyst believes Schwab keeps benefiting from the Dec 2015 rate hike as fee waivers declined in the third quarter as well. Further, rise in total client assets remain impressive.

Fiserv (NASDAQ:FISV) Q3 Earnings Top Estimates, Revenues Disappoint

The Zacks analyst thinks Fiserv's strong customer base & product portfolio are key catalysts but stricter regulations in the banking/financial services industry and stiff competition are concerning.n

Boston Scientific (NYSE:BSX) Q3 Revenues Beat, Grows Organically

The covering analyst think Boston Scientific posted strong organic growth due to perfect execution of long-term strategic plans.

Barclays (BCS) Q3 Results Depict Persistent Revenue Pressure

The Zacks analyst thinks Q3 earnings reflect continued pressure on revenue owing to its asset disposal efforts.

New Upgrades

Texas Instruments (NASDAQ:TXN) Q3 Results Solid; Guides Well

The Zacks analyst thinks the company's Q3 earnings beat came on the back of strengthening auto and industrial markets. Compelling product line and business differentiation were the other positives.

General Dynamics (NYSE:GD) Tops Q3 Earnings, Margin Up Y/Y

The covering analyst believes General Dynamics' better-than-expected Q3 earnings were boosted by its strong operating margin performance, particularly in the Aerospace segment; amid a revenue decline.

MKS Instruments (MKSI) Up to Strong Buy on Robust Q3 Results

The Zacks analyst thinks Northrop's better-than-expected Q3 results and its strong fundamentals encouraged management to raise FY16 View. Earnings also rose from the year ago quarter.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
New Downgrades

3M (MMM) Remains Vulnerable Despite Q3 Earnings Beat

Although 3M managed to beat third-quarter earnings by 1 cent, weak revenue growth and intense competition remain headwinds. 3M is also facing higher pension expenses as its workforce begins to retire.

Nielsen's (NLSN) Q3 Earnings Beat, Revenues Miss Marginally

With Nielsen delivering mixed Q3 results, the Zacks analyst believes that continued investments in technology and infrastructure could weigh on margins and profitability, going forward.

Robert Half (RHI) Q3 Earnings Beat, Sales Lag on Weak Growth

Though Robert Half beat its Q3 earnings, the Zacks analyst thinks that earnings declined as the company's clients are delaying hiring decisions. Also, fewer jobs were added in September than planned.



UNITEDHEALTH GP (UNH): Free Stock Analysis Report

3M CO (MMM): Free Stock Analysis Report

HONEYWELL INTL (HON): Free Stock Analysis Report

GENERAL MOTORS (GM): Free Stock Analysis Report

COLGATE PALMOLI (CL): Free Stock Analysis Report

BARCLAY PLC-ADR (BCS): Free Stock Analysis Report

BOEING CO (BA): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.